LYSAKER, NORWAY--(Marketwire - August 05, 2008) - Pronova BioPharma ASA reports record-high second quarter results, with 34.3 per cent revenue growth and 23.5 per cent EBITDA growth. Global end-user sales were up 55 per cent to USD 283.3 million (May YTD), driven by market share growth in the USA. The blockbuster potential of the company’s product is highlighted by a global run-rate in May 2008 of some USD 735 million (USD 475 million in May 2007).
